New arylsulfonylhydrazones of substituted benzaldehydes as anticancer agents.
Nineteen new arylsulfonylhydrazones of substituted benzaldehydes have been prepared. The antineoplastic activity of these compounds has been assessed against murine lymphocytic leukemia P-388 and Ehrlich ascites carcinoma (EAC). The compounds investigated have not reached the criteria of good antitumor activity. However, marginal activity in P-388 system has been exhibited by one of the tested derivatives, while two others have demonstrated mild anticancer activity against EAC.
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis*; D001547:Benzaldehydes / Q000138:chemical synthesis* / Q000494:pharmacology; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D006835:Hydrazones / Q000138:chemical synthesis* / Q000494:pharmacology; D007941:Leukemia P388 / Q000188:drug therapy; D008297:Male; D051379:Mice
D000970:Antineoplastic Agents; D001547:Benzaldehydes; D006835:Hydrazones